Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential
Search This Board: 
Last Post: 1/20/2018 8:01:36 PM - Followers: 151 - Board type: Free - Posts Today: 0

The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.

In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.

IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.

The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA News: Statement of Changes in Beneficial Ownership (4) 01/19/2018 04:54:40 PM
IDRA News: Current Report Filing (8-k) 01/17/2018 04:03:22 PM
IDRA News: Current Report Filing (8-k) 01/08/2018 08:46:15 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 01/05/2018 04:23:58 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 01/05/2018 04:23:58 PM
#3134   I am holding my core position tight as well. Citrati 01/20/18 08:01:36 PM
#3133   No, keep talking. I am listening, just Stockdoggy 01/20/18 03:44:50 PM
#3132   Starting to think I am a single ghost Citrati 01/19/18 11:09:08 PM
#3131   Smacking against that 200day again. I might Citrati 01/19/18 03:04:17 PM
#3130   IDRA stuck under the weekly 200day. Sold the Citrati 01/18/18 12:50:11 PM
#3129   Next up is 2.51 and then potentially 2.74 Citrati 01/15/18 10:26:33 PM
#3128   IDRA looks to be clearing 2.30's now to Citrati 01/10/18 08:47:23 PM
#3127   3 year weekly has 1st PT to 200day Citrati 01/06/18 06:00:19 PM
#3126   Sold trading shares when 2.33 didn't hold. Just Citrati 01/05/18 12:40:37 PM
#3125   Given that they stated their current cash position Phantom Lord 01/05/18 11:29:10 AM
#3124   Latest News. Citrati 01/05/18 10:25:48 AM
#3123   Here's the chart. Citrati 01/03/18 06:54:53 PM
#3122   Nice looking daily chart. Citrati 01/03/18 06:30:25 PM
#3121   "Where is Idera Pharmaceuticals' stock going? Where will Citrati 01/01/18 01:37:56 AM
#3120   Strong moves recently Imo Love to see this continue Cbdpotential 12/28/17 08:18:02 PM
#3119   Really looking forward to the future here And elsewhere Great Cbdpotential 12/28/17 05:35:08 AM
#3118   Green it is. Stacked ema's after price Citrati 12/27/17 11:36:40 PM
#3117   Agree! Looking good here imo I'm optimistic... Stay GREEN my friend :-) Cbdpotential 12/21/17 07:58:43 PM
#3116   So far looking great. Now let's get the Citrati 12/21/17 12:30:28 PM
#3115   Back in yesterday on the hold and confirmed Citrati 12/20/17 11:18:25 PM
#3114   $2 is the daily 200day. We got a Citrati 12/11/17 11:57:00 AM
#3113   1.74 is the daily S-1 fib pivot and Citrati 12/10/17 07:21:22 PM
#3112   I'll be looking to re-enter around $1.74, which noretreat 12/10/17 06:42:37 PM
#3111   Your welcome. Citrati 12/08/17 12:58:42 PM
#3110   I appreciate your response, as I am always Stockdoggy 12/08/17 12:32:54 PM
#3109   It is a combination of indicators, ma's, support/resistance Citrati 12/08/17 12:07:02 PM
#3108   Curious as to what kind of buy signal Stockdoggy 12/08/17 11:43:35 AM
#3107   Evaluate Pharma says IMO+ipi is one to watch jaybe 12/08/17 11:18:31 AM
#3106   & TY for chart sir! Farmmarket1 12/08/17 11:12:32 AM
#3105   I can buy back as of Monday with Farmmarket1 12/08/17 11:12:01 AM
#3104   Can't say for anyone else, but for me Citrati 12/08/17 10:55:25 AM
#3103   Wats the deal here guys? Short term, Farmmarket1 12/08/17 10:46:37 AM
#3102   Disclosure: Sold for profit on the confirmed Citrati 12/05/17 12:56:56 PM
#3101   Nice find. Thanks for posting. Citrati 12/02/17 01:39:04 AM
#3100   New 3GA patent app published yesterday... jaybe 12/01/17 01:15:21 PM
#3099   :-) Greeeeeeeeeen Cbdpotential 11/29/17 09:02:48 AM
#3098   Oh yeah, staying green. PM at $2.32. Citrati 11/29/17 08:39:00 AM
#3097   Nice move today Stay GREEN $idra :-D Cbdpotential 11/21/17 01:15:13 PM
#3096   IDRA Proxy statement. Citrati 11/17/17 11:27:48 PM
#3095   I have a full confidence on management , youssef 11/16/17 07:47:38 PM
#3094   Same here, in holddown mode for the other steppe 11/16/17 04:03:34 PM
#3093   Wouldn't hurt my feelings at all for the Citrati 11/16/17 01:06:56 PM
#3092   No I have enough of the other one youssef 11/16/17 09:04:59 AM
#3091   Hi Youssef, steppe 11/16/17 08:47:08 AM
#3090   I m buying idra weekly youssef 11/15/17 09:15:17 PM
#3089   Just a thought, if anyone still follows IDRA. Citrati 11/15/17 11:21:04 AM
#3088   Yes. Wish I had waited a couple more noretreat 11/10/17 04:12:05 PM
#3087   Lot of people unhappy with the capital raise. Citrati 11/10/17 03:40:56 PM
#3086   I think that is good news as well. Stockdoggy 11/10/17 12:24:45 PM
#3085   FYI short interest, got this from WSJ website noviceinvestor08 11/10/17 07:47:11 AM